Aldagen is a wholly-owned subsidiary of Cytomedix, Inc (BB:CMXI). The Aldagen subsidiary develops proprietary regenerative cell therapies in the vascular area. These cell therapeutics consist of a specific population of stem cells from a patient’s own bone marrow. Aldagen isolates these cells, which are typically less than 1% of all cells in bone marrow, using our proprietary technology. Based on preclinical studies and our clinical trials to date, Aldagen believes these cell populations have the potential to promote the regeneration of multiple types of cells and tissues, including the growth of new blood vessels, a process known as angiogenesis. Aldagen's product candidates are ALD-301 for the treatment of critical limb ischemia, ALD-201 for the treatment of ischemic heart failure and ALD-401 for the treatment of ischemic stroke.